In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer

In clinic, cetuximab, an anti-EGFR antibody, improves treatment outcomes in colorectal cancer (CRC). KRAS-mutant CRC is generally resistant to cetuximab, although difference of the sensitivity among KRAS-mutants has not been studied in detail. We previously developed the cancer tissue-originated sph...

Descripción completa

Detalles Bibliográficos
Autores principales: Tashiro, Takahiro, Okuyama, Hiroaki, Endo, Hiroko, Kawada, Kenji, Ashida, Yasuko, Ohue, Masayuki, Sakai, Yoshiharu, Inoue, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354432/
https://www.ncbi.nlm.nih.gov/pubmed/28301591
http://dx.doi.org/10.1371/journal.pone.0174151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354432/
https://www.ncbi.nlm.nih.gov/pubmed/28301591
http://dx.doi.org/10.1371/journal.pone.0174151

Ejemplares similares